

PROVISIONAL TECHNICAL EVALUATION REPORT FOR T NO 121 (COVID Medicines)

S.NO	Firm Name	Item Code	Item Name	Item Remarks	Status
1	Akums Drugs & Pharmaceuticals Limited	Firm Remarks : May be considered after submission of WHO-GMP Certificate and authorization letter. (Authorization was given to Mr.Sajan Sashidharan, but authorization letter not signed by any of the Director or Mg Director of the firm, signed by company secretary only.)			
		3456.07	Posaconazole Tablets 100mg		May be Considered
2	Bajaj Healthcare Limited	Firm Remarks : May be considered after submission of WHO-GMP Certificate.			
		3456.07	Posaconazole Tablets 100mg		May be Considered
3	BDR PHARMACEUTICALS INTERNATIONAL PVT. LTD	Firm Remarks : Firm may not be considered as the firm submitted product approval for loan licence. Firm not submitted WHO GMP Certificate. The firm given authorization to Mr. Bhavesh Shah and Manoj Kapoor, but all documents signed by sashi kala.			
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May not be considered
		3456.08	Posaconazole Inj 300mg		May not be considered
		3456.07	Posaconazole Tablets 100mg		May not be considered
4	Bharat Serums And Vaccines Ltd	Firm Remarks : May be considered after submission of WHO-GMP Certificate and authorization letter. Not submitted letter of Authorization given to Mr.Vishwadeep Srivastava to sign on tender Document. Note: EMD & Processing Fee paid online need to Verify.			
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May be Considered
5	EMCURE PHARMACEUTICALS LIMITED	Firm Remarks : May be considered after submission of WHO-GMP Certificate and Valid NCC. Annexure III,V,VII with signature of authorized person/Listed Director. Clarification regarding authorization letter as not signed by listed Directors.			
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May be Considered
6	LYKA LABS LIMITED	Firm Remarks : May be considered after submission of WHO-GMP Certificate.			
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May be Considered
7	MEDISKY PHARMACEUTICALS	Firm Remarks : May be considered after submission of WHO-GMP Certificate.			

S.NO	Firm Name	Item Code	Item Name	Item Remarks	Status	
		3456.07	Posaconazole Tablets 100mg		May be Considered	
8	MSN Laboratories Ltd	Firm Remarks : May be considered after submission of WHO-GMP Certificate. Note : Firm have to submit clarity on DD's of processing fee & EMD				
		3456.08	Posaconazole Inj 300mg		May be Considered	
		3456.07	Posaconazole Tablets 100mg		May be Considered	
9	Mylan Laboratories Limited	Firm Remarks : Firm may not be considered as the firm submitted product approval for loan licence. Firm not submitted WHO GMP Certificate.				
		3456.02	Remdesivir 100mg Inj (lyophilized)		May not be considered	
10	Mylan Pharamaceuticals Pvt Ltd	Firm Remarks : Firm may be considered after submission of WHO-GMP certificate of mfg, Mfg Licence copy, Product approval of mfg, Wholesale license copy of importing premises and NCC of importing premises. Note : Firm have to submit clarity on DD's of processing fee & EMD				
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May not be considered	
11	NATCO PHARMA LTD	Firm Remarks : May be considered after submission of WHO-GMP Certificate and authorization letter. Authorization letter to M/S Medihauxe pharma pvt ltd given by K Srivatsava, Vice president, Natco. But not submitted authorization letter given to K Srivatsava, Vice president.				
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May be Considered	
		3456.08	Posaconazole Inj 300mg		May be Considered	

Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00.PM on 20.09.2021 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 121(COVID MED) TEC Report.